A record-high $6.9 million was raised for VeloSano in 2022, 100% of which will support lifesaving cancer research at Cleveland Clinic and Cleveland Clinic Children’s. The year-round fundraising movement has brought in a cumulative total of more than $37 million since its inception in 2014.
The total amount raised was announced in a video featuring the many ways funds were raised for VeloSano throughout the year. This milestone was made possible by the entire VeloSano community, which includes Bike to Cure Riders and Volunteers, Virtual Fundraisers, Trike & Bike Junior Riders, Donors, VeloSano Victors and Corporate Partners.
“Everyone knows someone affected by cancer and it can be empowering to take action together,” said Alex A. Adjei, M.D., Ph.D., chair of Cleveland Clinic Taussig Cancer Institute. “Cleveland Clinic is a leader in cancer care and research, and the support we receive through VeloSano enables us to expand our work and our impact.”
Cancer researchers across the Cleveland Clinic enterprise apply for funds raised for VeloSano, with the money being awarded to research proposals with the greatest promise. Thus far, VeloSano has supported more than 200 cancer research projects. Those projects often go on to earn research grants from the National Institutes of Health and other entities. The total return from additional, outside funding now surpasses $22 million, making the total impact of VeloSano more than $59 million.
VeloSano has gained significant momentum in raising money for cancer research at Cleveland Clinic due to the support of its partners, including but not limited to, the Kohl Fund, the Cleveland Guardians, Adcom, Jones Day, Lexus, Advance Ohio/The Plain Dealer, AstraZeneca, Hileman Group, House of LaRose / Michelob Ultra, KeyBank, The Lerner Foundation, and TransDigm Group.
"We’re grateful for everyone who has helped us turn this event into a movement over the last decade resulting in a record-setting year in 2022," said Stewart Kohl, founder of VeloSano and Co-CEO of The Riverside Company. "It’s incredibly rewarding for us to be able to go on the offensive against cancer, funding cutting-edge research helping to extend and improve the quality of lives."